Parabilis Medicines, Inc. (PBLS)
Nasdaq: PBLS · Pharmaceutical Preparations · filing with the SEC since 2015
Who owns Parabilis Medicines, Inc.
As filed with the SECHolders of 5% or more
3
RA Capital Management, L.P. holds 23.8% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13D filed Jun 18, 2026 says.
Directors and officers
19
report now, of 19 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
RA Capital Management, L.P.
SCHEDULE 13D · filed Jun 18, 2026 · Common Stock, par value $0.0001 per share
Fmr LLC
SCHEDULE 13G · filed Aug 6, 2026 · COMMON STOCK
ARCH Venture Fund XII, L.P.
SCHEDULE 13G · filed Aug 14, 2026 · Common Stock, $0.0001 par value
What PBLS reports owning in othersstakes of 5% or more, and other ties
Parabilis Medicines, Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
12purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$431Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window4 of 34 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | director | 0 | $0 | 0 | 6 | $6.9M |
| Sebulsky Alan | director | 0 | $0 | 0 | 4 | $700,000 |
| Ra Capital Nexus Fund III, L.P. | director | 0 | $0 | 0 | 2 | $424M |
| Soleus Capital Group, LLC | 10% owner | 0 | $0 | 0 | 2 | $10.0M |